Legal & General Group Plc Sells 18,302 Shares of Guardant Health, Inc. (NASDAQ:GH)

Legal & General Group Plc reduced its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 9.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 177,187 shares of the company's stock after selling 18,302 shares during the quarter. Legal & General Group Plc owned about 0.14% of Guardant Health worth $5,413,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in GH. Bank of Montreal Can acquired a new position in Guardant Health during the fourth quarter worth about $248,000. Federated Hermes Inc. increased its position in Guardant Health by 11.5% during the 4th quarter. Federated Hermes Inc. now owns 962,722 shares of the company's stock worth $29,411,000 after purchasing an additional 99,072 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Guardant Health in the 4th quarter valued at approximately $420,000. Trexquant Investment LP lifted its stake in Guardant Health by 4.1% in the 4th quarter. Trexquant Investment LP now owns 474,171 shares of the company's stock valued at $14,486,000 after purchasing an additional 18,461 shares during the last quarter. Finally, California Public Employees Retirement System boosted its position in Guardant Health by 13.8% in the fourth quarter. California Public Employees Retirement System now owns 178,470 shares of the company's stock valued at $5,452,000 after buying an additional 21,674 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GH has been the subject of several research analyst reports. Stephens reiterated an "overweight" rating and set a $55.00 price target on shares of Guardant Health in a report on Wednesday, March 26th. The Goldman Sachs Group upped their target price on Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Stifel Nicolaus lifted their price target on Guardant Health from $45.00 to $53.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Scotiabank boosted their price target on Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Monday, February 24th. Finally, Raymond James reiterated an "outperform" rating and issued a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Twenty equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $49.00.

Guardant Health Stock Up 4.4 %

NASDAQ:GH traded up $1.93 during trading hours on Wednesday, reaching $45.73. The company had a trading volume of 2,316,558 shares, compared to its average volume of 2,140,050. Guardant Health, Inc. has a twelve month low of $16.77 and a twelve month high of $50.89. The firm has a market cap of $5.64 billion, a price-to-earnings ratio of -12.85 and a beta of 1.45. The business's 50-day simple moving average is $43.43 and its two-hundred day simple moving average is $36.76.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. As a group, equities analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.